AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mueller, S. C.
Right arrow Articles by Drewelow, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mueller, S. C.
Right arrow Articles by Drewelow, B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1557-1560, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1557-1560.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Piperacillin-Tazobactam in Anuric Intensive Care Patients during Continuous Venovenous Hemodialysis

Silke C. Mueller,1* Jolanta Majcher-Peszynska,1 Heiko Hickstein,2 Astrid Francke,3 Annette Pertschy,4 Martin Schulz,2 Ralf Mundkowski,1 and Bernd Drewelow1

Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology,1 Clinic for Internal Medicine,2 Clinic for Anesthesiology and Intensive Care Medicine,3 Clinic for Surgery, University of Rostock, D-18057 Rostock, Germany4

Received 16 January 2001/ Returned for modification 15 July 2001/ Accepted 25 January 2002

The pharmacokinetics of piperacillin-tazobactam were investigated in eight anuric intensive care patients treated by continuous venovenous hemodialysis (CVVHD). The elimination half-life of piperacillin was 4.3 ± 1.2 h, and that of tazobactam was 5.6 ± 1.3 h. The contribution of CVVHD to the overall elimination was relevant (>25%) for both drugs.

* Corresponding author. Mailing address: Institute of Experimental and Clinical Pharmacology and Toxicology, Department of Clinical Pharmacology, University of Rostock, Schillingallee 70, D-18057 Rostock, Germany. Phone: 49-381-494-5959. Fax: 49-381-494-5782. E-mail: silke.mueller{at}med.uni-rostock.de.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1557-1560, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1557-1560.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.